Vaccines against invasive Salmonella disease: Current status and future directions

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 6, 2014, Pages 1478-1493

  MacLennan, Calman A ^a,b   Martin, Laura B ^a   Micoli, Francesca ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Enteric; Global health; Glycoconjugate; GMMA; Nontyphoidal; Salmonella; Typhoid; Vaccines

Indexed keywords

SALMONELLOSIS VACCINE;

AFRICA SOUTH OF THE SAHARA; ASIA; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; SALMONELLA INFECTIONS; TRENDS;

AFRICA SOUTH OF THE SAHARA; ASIA; DRUG DISCOVERY; HUMANS; SALMONELLA INFECTIONS; SALMONELLA VACCINES;

EID: 84905826930     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29054     Document Type: Review

References (176)

1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209-22; PMID:23680352; http://dx.doi.org/10.1016/S0140-6736(13)60844-2
2. Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y. Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis 2012; 12:480-7; PMID:22632186; http://dx.doi.org/10.1016/S1473-3099(12)70028-2
3. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346-53; PMID:15298225
4. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:417-32; PMID:20510282; http://dx.doi.org/10.1016/S1473-3099(10)70072-4
5. Ochiai RL, Wang X, von Seidlein L, Yang J, Bhutta ZA, Bhattacharya SK, Agtini M, Deen JL, Wain J, Kim DR, et al. Salmonella paratyphi A rates, Asia. Emerg Infect Dis 2005; 11:1764-6; PMID:16318734; http://dx.doi.org/10.3201/ eid1111.050168
6. Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, Rao M, Naficy A, Clemens JD, Bhan MK. Typhoid fever in children aged less than 5 years. Lancet 1999; 354:734-7; PMID:10475185; http://dx.doi.org/10.1016/S0140-6736(98)09001-1
7. Saha SK, Baqui AH, Hanif M, Darmstadt GL, Ruhulamin M, Nagatake T, Santosham M, Black RE. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001; 20:521-4; PMID:11368111; http://dx.doi.org/10.1097/00006454-200105000-00010
8. Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N, Naheed A, Nair GB, Luby S, Breiman RF. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005; 11:326-9; PMID:15752457; http://dx.doi.org/ 10.3201/eid1102.040422
9. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. Lancet 2012; 379:2489-99; PMID:22587967; http://dx.doi.org/10.1016/ S0140-6736(11)61752-2
10. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, et al.; RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863-75; PMID:22007715; http://dx.doi.org/10.1056/NEJMoa1102287
11. MacLennan CA, Levine MM. Invasive nontyphoidal Salmonella disease in Africa: current status. Expert Rev Anti Infect Ther 2013; 11:443-6; PMID:23627848; http://dx.doi.org/10.1586/eri.13.27
12. Roumagnac P, Weill FX, Dolecek C, Baker S, Brisse S, Chinh NT, Le TA, Acosta CJ, Farrar J, Dougan G, et al. Evolutionary history of Salmonella typhi. Science 2006; 314:1301-4; PMID:17124322; http://dx.doi.org/10.1126/science. 1134933
13. Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, Harris D, Clarke L, Whitehead S, Sangal V, et al. Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res 2009; 19:2279-87; PMID:19901036; http://dx.doi.org/10.1101/gr.091017.109
14. Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, Al-Mashhadani MN, Kariuki S, Msefula CL, Gordon MA, de Pinna E, et al. Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa. Nat Genet 2012; 44:1215-21; PMID:23023330; http://dx.doi.org/10.1038/ng.2423
15. Kariuki S, Revathi G, Gakuya F, Yamo V, Muyodi J, Hart CA. Lack of clonal relationship between non-typhi Salmonella strain types from humans and those isolated from animals living in close contact. FEMS Immunol Med Microbiol 2002; 33:165-71; PMID:12110478; http://dx.doi.org/10.1111/j.1574-695X.2002.tb00587.x
16. Kariuki S, Revathi G, Kariuki N, Kiiru J, Mwituria J, Muyodi J, Githinji JW, Kagendo D, Munyalo A, Hart CA. Invasive multidrug-resistant nontyphoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission? J Med Microbiol 2006; 55:585-91; PMID:16585646; http://dx.doi.org/10.1099/jmm.0.46375- 0
17. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998; 316:110-6; PMID:9462316; http://dx.doi.org/10.1136/bmj.316.7125.110
18. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007; 25:7848-57; PMID:17928109; http://dx.doi.org/10.1016/j.vaccine. 2007.08.027
19. Khan MI, Ochiai RL, Clemens JD. Population impact of Vi capsular polysaccharide vaccine. Expert Rev Vaccines 2010; 9:485-96; PMID:20450323; http://dx.doi.org/10.1586/erv.10.43
20. Gordon MA, Graham SM, Walsh AL, Wilson L, Phiri A, Molyneux E, Zijlstra EE, Heyderman RS, Hart CA, Molyneux ME. Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis 2008; 46:963-9; PMID:18444810; http://dx.doi.org/10.1086/529146
21. Olopoenia LA, King AL. Widal agglutination test - 100 years later: still plagued by controversy. Postgrad Med J 2000; 76:80-4; PMID:10644383; http://dx.doi.org/10.1136/pmj.76.892.80
22. Mabey DC, Brown A, Greenwood BM. Plasmodium falciparum malaria and Salmonella infections in Gambian children. J Infect Dis 1987; 155:1319-21; PMID:3553352; http://dx.doi.org/10.1093/infdis/155.6.1319
23. Graham SM, English M. Non-typhoidal salmonellae: a management challenge for children with community-acquired invasive disease in tropical African countries. Lancet 2009; 373:267-9; PMID:19150705; http://dx.doi.org/10.1016/ S0140-6736(09)60073-8
24. Mastroeni P, Villarreal-Ramos B, Hormaeche CE. Adoptive transfer of immunity to oral challenge with virulent salmonellae in innately susceptible BALB/c mice requires both immune serum and T cells. Infect Immun 1993; 61:3981-4; PMID:8359920
25. Salerno-Goncalves R, Pasetti MF, Sztein MB. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 2002; 169:2196-203; PMID:12165550; http://dx.doi.org/10.4049/jimmunol.169.4.2196
26. Fields PI, Swanson RV, Haidaris CG, Heffron F. Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc Natl Acad Sci U S A 1986; 83:5189-93; PMID:3523484; http://dx.doi.org/10.1073/pnas. 83.14.5189
27. Mastroeni P, Vazquez-Torres A, Fang FC, Xu Y, Khan S, Hormaeche CE, Dougan G. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. II. Effects on microbial proliferation and host survival in vivo. J Exp Med 2000; 192:237-48; PMID:10899910; http://dx.doi.org/10.1084/jem.192.2.237
28. Vazquez-Torres A, Jones-Carson J, Mastroeni P, Ischiropoulos H, Fang FC. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. I. Effects on microbial killing by activated peritoneal macrophages in vitro. J Exp Med 2000; 192:227-36; PMID:10899909; http://dx.doi.org/10.1084/jem.192.2.227
29. Sinha K, Mastroeni P, Harrison J, de Hormaeche RD, Hormaeche CE. Salmonella typhimurium aroA, htrA, and aroD htrA mutants cause progressive infections in athymic (nu/nu) BALB/c mice. Infect Immun 1997; 65:1566-9; PMID:9119506
30. McSorley SJ, Jenkins MK. Antibody is required for protection against virulent but not attenuated Salmonella enterica serovar typhimurium. Infect Immun 2000; 68:3344-8; PMID:10816483; http://dx.doi.org/10.1128/IAI.68.6.3344- 3348.2000
31. Mastroeni P, Grant A, Restif O, Maskell D. A dynamic view of the spread and intracellular distribution of Salmonella enterica. Nat Rev Microbiol 2009; 7:73-80; PMID:19079353; http://dx.doi.org/10.1038/nrmicro2034
32. Blanden RV, Mackaness GB, Collins FM. Mechanisms of acquired resistance in mouse typhoid. J Exp Med 1966; 124:585-600; PMID:4958757; http://dx.doi.org/10.1084/jem.124.4.585
33. Mackaness GB, Blanden RV, Collins FM. Host-parasite relations in mouse typhoid. J Exp Med 1966; 124:573-83; PMID:5922285; http://dx.doi.org/10.1084/ jem.124.4.573
34. Lazarus GM, Neu HC. Agents responsible for infection in chronic granulomatous disease of childhood. J Pediatr 1975; 86:415-7; PMID:1113230; http://dx.doi.org/10.1016/S0022-3476(75)80975-9
35. Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr 1989; 114:555-60; PMID:2784499; http://dx.doi.org/10.1016/S0022-3476(89)80693-6
36. MacLennan C, Fieschi C, Lammas DA, Picard C, Dorman SE, Sanal O, MacLennan JM, Holland SM, Ottenhoff TH, Casanova JL, et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis 2004; 190:1755-7; PMID:15499529; http://dx.doi.org/10.1086/425021
37. Bustamante J, Boisson-Dupuis S, Jouanguy E, Picard C, Puel A, Abel L, Casanova JL. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr Opin Immunol 2008; 20:39-48; PMID:18083507; http://dx.doi.org/10.1016/j.coi.2007.10.005
38. Prando C, Samarina A, Bustamante J, Boisson-Dupuis S, Cobat A, Picard C, AlSum Z, Al-Jumaah S, Al-Hajjar S, Frayha H, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) 2013; 92:109-22; PMID:23429356; http://dx.doi.org/10.1097/MD.0b013e31828a01f9
39. MacLennan CA, Gondwe EN, Msefula CL, Kingsley RA, Thomson NR, White SA, Goodall M, Pickard DJ, Graham SM, Dougan G, et al. The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest 2008; 118:1553-62; PMID:18357343; http://dx.doi.org/10.1172/JCI33998
40. Gondwe EN, Molyneux ME, Goodall M, Graham SM, Mastroeni P, Drayson MT, MacLennan CA. Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc Natl Acad Sci U S A 2010; 107:3070-5; PMID:20133627; http://dx.doi.org/10.1073/ pnas.0910497107
41. Siggins MK, O'Shaughnessy CM, Pravin J, Cunningham AF, Henderson IR, Drayson MT, Maclennan CA. Differential timing of antibody-mediated phagocytosis and cell-free killing of invasive African Salmonella allows immune evasion. Eur J Immunol 2014; 44:1093-8; PMID:24375424; http://dx.doi.org/10.1002/eji. 201343529
42. Gordon MA, Banda HT, Gondwe M, Gordon SB, Boeree MJ, Walsh AL, Corkill JE, Hart CA, Gilks CF, Molyneux ME. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS 2002; 16:1633-41; PMID:12172085; http://dx.doi.org/10.1097/00002030-200208160- 00009
43. MacLennan CA, Gilchrist JJ, Gordon MA, Cunningham AF, Cobbold M, Goodall M, Kingsley RA, van Oosterhout JJ, Msefula CL, Mandala WL, et al. Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science 2010; 328:508-12; PMID:20413503; http://dx.doi.org/10.1126/science. 1180346
44. Gordon MA, Gordon SB, Musaya L, Zijlstra EE, Molyneux ME, Read RC. Primary macrophages from HIV-infected adults show dysregulated cytokine responses to Salmonella, but normal internalization and killing. AIDS 2007; 21:2399-408; PMID:18025876; http://dx.doi.org/10.1097/QAD.0b013e3282f25107
45. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, Godinez I, Sankaran S, Paixao TA, Gordon MA, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008; 14:421-8; PMID:18376406; http://dx.doi.org/10.1038/nm1743
46. Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, Yang LY, Chow SC, Morpeth SC, Reyburn H, Njau BN, et al. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. Clin Infect Dis 2011; 52:341-8; PMID:21217181; http://dx.doi.org/10.1093/cid/ciq103
47. MacLennan CA. Chapter 17 The challenge of developing global health vaccines against the invasive salmonelloses: enteric fever and invasive nontyphoidal Salmonella disease. Advanced Vaccine Research Methods for the Decade of Vaccines, Editors Bagnoli F, Rappuoli R, Publisher Caister Academic Press
48. Brenner FW, Villar RG, Angulo FJ, Tauxe R, Swaminathan B. Salmonella nomenclature. J Clin Microbiol 2000; 38:2465-7; PMID:10878026
49. Grimont PA. D and Weill, F. X. WHO Collaborating Centre for Reference and Research on Salmonellae. Antigenic formulae of Salmonella serovars 2007 9th edition. (cited 2007). Available from: https://www.pasteur.fr/ip/portal/action/ WebdriveActionEvent/oid/01s-000036-089.
50. Simon R, Tennant SM, Wang JY, Schmidlein PJ, Lees A, Ernst RK, Pasetti MF, Galen JE, Levine MM. Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun 2011; 79:4240-9; PMID:21807909; http://dx.doi.org/10.1128/IAI.05484-11
51. Watson DC, Robbins JB, Szu SC. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun 1992; 60:4679-86; PMID:1383154
52. Carlin NI, Svenson SB, Lindberg AA. Role of monoclonal O-antigen antibody epitope specificity and isotype in protection against experimental mouse typhoid. Microb Pathog 1987; 2:171-83; PMID:2467161; http://dx.doi.org/10.1016/ 0882-4010(87)90019-2
53. Singh SP, Williams YU, Benjamin WH, Klebba PE, Boyd D. Immunoprotection by monoclonal antibodies to the porins and lipopolysaccharide of Salmonella typhimurium. Microb Pathog 1996; 21:249-63; PMID:8905614; http://dx.doi.org/10. 1006/mpat.1996.0059
54. Rondini S, Lanzilao L, Necchi F, O'Shaughnessy CM, Micoli F, Saul A, MacLennan CA. Invasive African Salmonella Typhimurium induces bactericidal antibodies against O-antigens. Microb Pathog 2013; 63:19-23; PMID:23756206; http://dx.doi.org/10.1016/j.micpath.2013.05.014
55. MacLennan CA, Tennant SM. Comparing the roles of antibodies to nontyphoidal Salmonella enterica in high- and low-income countries and implications for vaccine development. Clin Vaccine Immunol 2013; 20:1487-90; PMID:23904457; http://dx.doi.org/10.1128/CVI.00465-13
56. Trebicka E, Jacob S, Pirzai W, Hurley BP, Cherayil BJ. Role of antilipopolysaccharide antibodies in serum bactericidal activity against Salmonella enterica serovar Typhimurium in healthy adults and children in the United States. Clin Vaccine Immunol 2013; 20:1491-8; PMID:23803904; http://dx.doi.org/10.1128/CVI.00289-13
57. Jansen AM, Hall LJ, Clare S, Goulding D, Holt KE, Grant AJ, Mastroeni P, Dougan G, Kingsley RA. A Salmonella Typhimurium-Typhi genomic chimera: a model to study Vi polysaccharide capsule function in vivo. PLoS Pathog 2011; 7:e1002131; PMID:21829346; http://dx.doi.org/10.1371/journal.ppat.1002131
58. Osawa E, Muschel LH. Muschel LH. The bacteridical actions of O and Vi antibodies against Salmonella Typhosa. J Immunol 1964; 92:281-5; PMID:14160449
59. Pulickal AS, Gautam S, Clutterbuck EA, Thorson S, Basynat B, Adhikari N, Makepeace K, Rijpkema S, Borrow R, Farrar JJ, et al. Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. Clin Vaccine Immunol 2009; 16:1413-9; PMID:19710294; http://dx.doi.org/ 10.1128/CVI.00245-09
60. Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, Chu C, Schiloach J, Robbins JB, Schneerson R, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003; 349:1390-1; PMID:14523155; http://dx.doi.org/10.1056/NEJM200310023491423
61. Thiem VD, Lin FY, Canh G, Son NH, Anh DD, Mao ND, Chu C, Hunt SW, Robbins JB, Schneerson R, et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011; 18:730-5; PMID:21411598; http://dx.doi.org/10.1128/CVI.00532-10
62. Szu SC. Development of Vi conjugate - a new generation of typhoid vaccine. Expert Rev Vaccines 2013; 12:1273-86; PMID:24156285; http://dx.doi.org/10.1586/14760584.2013.845529
63. Szu SC, Klugman KP, Hunt S. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children. Vaccine 2014; 32:2359-63; PMID:24630869; http://dx.doi.org/10.1016/j.vaccine.2014.02.050
64. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-20; PMID:19214194; http://dx.doi.org/10.1038/nri2494
65. MacLennan CA. Vaccines for low-income countries. Semin Immunol 2013; 25:114-23; PMID:23757292; http://dx.doi.org/10.1016/j.smim.2013.05.004
66. Eom JS, Seok Kim J, Im Jang J, Kim BH, Young Yoo S, Hyeon Choi J, Bang IS, Lee IS, Keun Park Y. Enhancement of host immune responses by oral vaccination to Salmonella enterica serovar Typhimurium harboring both FliC and FljB flagella. PLoS One 2013; 8:e74850; PMID:24069357; http://dx.doi.org/10. 1371/journal.pone.0074850
67. Bobat S, Flores-Langarica A, Hitchcock J, Marshall JL, Kingsley RA, Goodall M, Gil-Cruz C, Serre K, Leyton DL, Letran SE, et al. Soluble flagellin, FliC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of Salmonella typhimurium infection. Eur J Immunol 2011; 41:1606-18; PMID:21469112; http://dx.doi.org/10.1002/eji.201041089
68. Simon R, Wang JY, Boyd MA, Tulapurkar ME, Ramachandran G, Tennant SM, Pasetti M, Galen JE, Levine MM. Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates. PLoS One 2013; 8:e64680; PMID:23741368; http://dx.doi.org/10. 1371/journal.pone.0064680
69. Cunningham AF, Khan M, Ball J, Toellner KM, Serre K, Mohr E, MacLennan IC. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol 2004; 34:2986-95; PMID:15384042; http://dx.doi.org/10.1002/eji.200425403
70. Flores-Langarica A, Marshall JL, Hitchcock J, Cook C, Jobanputra J, Bobat S, Ross EA, Coughlan RE, Henderson IR, Uematsu S, et al. Systemic flagellin immunization stimulates mucosal CD103+ dendritic cells and drives Foxp3+ regulatory T cell and IgA responses in the mesenteric lymph node. J Immunol 2012; 189:5745-54; PMID:23152564; http://dx.doi.org/10.4049/jimmunol.1202283
71. Gat O, Galen JE, Tennant S, Simon R, Blackwelder WC, Silverman DJ, Pasetti MF, Levine MM. Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines. PLoS Negl Trop Dis 2011; 5:e1373; PMID:22069504; http://dx.doi.org/10.1371/journal.pntd. 0001373
72. Cunningham AF, Gaspal F, Serre K, Mohr E, Henderson IR, Scott-Tucker A, Kenny SM, Khan M, Toellner KM, Lane PJ, et al. Salmonella induces a switched antibody response without germinal centers that impedes the extracellular spread of infection. J Immunol 2007; 178:6200-7; PMID:17475847; http://dx.doi.org/10. 4049/jimmunol.178.10.6200
73. Gil-Cruz C, Bobat S, Marshall JL, Kingsley RA, Ross EA, Henderson IR, Leyton DL, Coughlan RE, Khan M, Jensen KT, et al. The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response. Proc Natl Acad Sci U S A 2009; 106:9803-8; PMID:19487686; http://dx.doi.org/10.1073/pnas.0812431106
74. Lee SJ, Liang L, Juarez S, Nanton MR, Gondwe EN, Msefula CL, Kayala MA, Necchi F, Heath JN, Hart P, et al. Identification of a common immune signature in murine and human systemic Salmonellosis. Proc Natl Acad Sci U S A 2012; 109:4998-5003; PMID:22331879; http://dx.doi.org/10.1073/pnas.1111413109
75. Liang L, Juarez S, Nga TV, Dunstan S, Nakajima-Sasaki R, Davies DH, McSorley S, Baker S, Felgner PL. Immune profiling with a Salmonella Typhi antigen microarray identifies new diagnostic biomarkers of human typhoid. Sci Rep 2013; 3:1043; PMID:23304434; http://dx.doi.org/10.1038/srep01043
76. Charles RC, Liang L, Khanam F, Sayeed MA, Hung C, Leung DT, Baker S, Ludwig A, Harris JB, Larocque RC, et al. Immunoproteomic analysis of antibody in lymphocyte supernatant in patients with typhoid fever in Bangladesh. Clin Vaccine Immunol 2014; 21:280-5; PMID:24371257
77. Barat S, Willer Y, Rizos K, Claudi B, Mazé A, Schemmer AK, Kirchhoff D, Schmidt A, Burton N, Bumann D. Immunity to intracellular Salmonella depends on surface-associated antigens. PLoS Pathog 2012; 8:e1002966; PMID:23093937; http://dx.doi.org/10.1371/journal.ppat.1002966
78. Maskey AP, Day JN, Phung QT, Thwaites GE, Campbell JI, Zimmerman M, Farrar JJ, Basnyat B. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006; 42:1247-53; PMID:16586383; http://dx.doi.org/10.1086/ 503033
79. Kariuki S, Revathi G, Kiiru J, Mengo DM, Mwituria J, Muyodi J, Munyalo A, Teo YY, Holt KE, Kingsley RA, et al. Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia.J Clin Microbiol 2010; 48:2171-6; PMID:20392916; http://dx.doi.org/10.1128/JCM.01983-09
80. Breiman RF, Cosmas L, Njuguna H, Audi A, Olack B, Ochieng JB, Wamola N, Bigogo GM, Awiti G, Tabu CW, et al. Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa. PLoS One 2012; 7:e29119; PMID:22276105; http://dx.doi.org/10.1371/journal.pone.0029119
81. Tabu C, Breiman RF, Ochieng B, Aura B, Cosmas L, Audi A, Olack B, Bigogo G, Ongus JR, Fields P, et al. Differing burden and epidemiology of non-Typhi Salmonella bacteremia in rural and urban Kenya, 2006-2009. PLoS One 2012; 7:e31237; PMID:22363591; http://dx.doi.org/10.1371/journal.pone.0031237
82. Feasey NA, Heyderman RS, Gordon MA. Salmonella blood-stream infection in Malawi: A fall in nontyphoidal Salmonella and an outbreak of Typhoid. 8th International Conference of Typhoid Fever and Other Invasive Salmonelloses. Dhaka, Bangladesh: 2013.
83. Tennant SM, Diallo S, Levy H, Livio S, Sow SO, Tapia M, Fields PI, Mikoleit M, Tamboura B, Kotloff KL, et al. Identification by PCR of non-typhoidal Salmonella enterica serovars associated with invasive infections among febrile patients in Mali. PLoS Negl Trop Dis 2010; 4:e621; PMID:20231882; http://dx.doi.org/10.1371/journal.pntd.0000621
84. Simon R, Levine MM. Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Hum Vaccin Immunother 2012; 8:494-8; PMID:22370510; http://dx.doi.org/10.4161/hv.19158
85. Holt KE, Parkhill J, Mazzoni CJ, Roumagnac P, Weill FX, Goodhead I, Rance R, Baker S, Maskell DJ, Wain J, et al. High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi. Nat Genet 2008; 40:987-93; PMID:18660809; http://dx.doi.org/10.1038/ng.195
86. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33:530-41; PMID:21029963; http://dx.doi.org/10.1016/ j.immuni.2010.09.017
87. Pfeiffer RW. Experimentelle Untersuchungen zur Frage der Schutzimpfung des Menschen gegen Typhus abdominalis. Dtsch Med Wochenschr 1896; 22:3; http://dx.doi.org/10.1055/s-0029-1204734
88. Wright AE, Leishman WB. Remarks on the Results which have been Obtained by the Antityphoid Inoculations and on the Methods which have been Employed in the Preparation of the Vaccine. Br Med J 1900; 1:122-9; PMID:20758818; http://dx.doi.org/10.1136/bmj.1.2038.122
89. Hawley PR, Simmons JS. The Effectiveness of Vaccines Used for the Prevention of Typhoid Fever in the United States Army and Navy. Am J Public Health Nations Health 1934; 24:689-709; PMID:18014010; http://dx.doi.org/10. 2105/AJPH.24.7.689
90. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ 1994; 72:957-71; PMID:7867143
91. Wahdan MH, Sippel JE, Mikhail IA, Rahka AE, Anderson ES, Sparks HA, Cvjetanović B. Controlled field trial of a typhoid vaccine prepared with a nonmotile mutant of Salmonella typhi Ty2. Bull World Health Organ 1975; 52:69-73; PMID:1082383
92. Germanier R, Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975; 131:553-8; PMID:1092768; http://dx.doi.org/10.1093/infdis/ 131.5.553
93. Kantele A, Pakkanen SH, Karttunen R, Kantele JM. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines - a randomized trial. PLoS One 2013; 8:e60583; PMID:23593253; http://dx.doi.org/10.1371/journal.pone.0060583
94. Cryz SJ Jr., Vanprapar N, Thisyakorn U, Olanratmanee T, Losonsky G, Levine MM, Chearskul S. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun 1993; 61:1149-51; PMID:8432597
95. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11(Suppl 3):S552-67; PMID:2669099; http://dx.doi.org/10.1093/clinids/11.Supplement-3.S552
96. Ohtake S, Martin R, Saxena A, Pham B, Chiueh G, Osorio M, Kopecko D, Xu D, Lechuga-Ballesteros D, Truong-Le V. Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines. Vaccine 2011; 29:2761-71; PMID:21300096; http://dx.doi.org/10.1016/j.vaccine.2011.01.093
97. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007; 45(Suppl 1):S24-8; PMID:17582564; http://dx.doi.org/10.1086/518141
98. Pakkanen SH, Kantele JM, Kantele A. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine 2012; 30:6047-53; PMID:22858557; http://dx.doi.org/10.1016/j.vaccine.2012.07.051
99. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol 2012; 19:825-34; PMID:22492745; http://dx.doi.org/10.1128/CVI.00058-12
100. Kantele A, Pakkanen SH, Siitonen A, Karttunen R, Kantele JM. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against nontyphoid salmonella? Vaccine 2012; 30:7238-45; PMID:23084770; http://dx.doi.org/10.1016/ j.vaccine.2012.10.002
101. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, Dutta S, Donner A, Kanungo S, Park JK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335-44; PMID:19625715; http://dx.doi.org/10.1056/NEJMoa0807521
102. Khan MI, Soofi SB, Ochiai RL, Habib MA, Sahito SM, Nizami SQ, Acosta CJ, Clemens JD, Bhutta ZA; DOMI Typhoid Karachi Vi Effectiveness Study Group. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 2012; 30:5389-95; PMID:22721899; http://dx.doi.org/10.1016/j.vaccine.2012.06.015
103. Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011; 10:307-22; PMID:21434799; http://dx.doi.org/10.1586/erv.11.8
104. Wahdan MH, Sérié C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis 1982; 145:292-5; PMID:7037982; http://dx.doi.org/10.1093/infdis/145.3.292
105. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1:1049-52; PMID:2883393; http://dx.doi.org/10.1016/S0140-6736(87)90480-6
106. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990; 336:891-4; PMID:1976928; http://dx.doi.org/10.1016/0140-6736(90)92266-K
107. Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R; Chilean Typhoid Committee. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Vaccine 1990; 8:81-4; PMID:2180234; http://dx.doi.org/10.1016/0264-410X(90) 90183-M
108. Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, Haryanto P, Suprijanto E, Witham ND, Hoffman SL. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991; 338:1055-9; PMID:1681365; http://dx.doi.org/10.1016/0140-6736(91)91910-M
109. Murphy JR, Grez L, Schlesinger L, Ferreccio C, Baqar S, Muñoz C, Wasserman SS, Losonsky G, Olson JG, Levine MM. Immunogenicity of Salmonella typhi Ty21a vaccine for young children. Infect Immun 1991; 59:4291-3; PMID:1937790
110. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17(Suppl 2):S22-7; PMID:10506405; http://dx.doi.org/10.1016/S0264-410X(99) 00231-5
111. Salerno-Gonçalves R, Wahid R, Sztein MB. Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires. Infect Immun 2005; 73:3521-30; PMID:15908381; http://dx.doi.org/10.1128/IAI.73.6.3521- 3530.2005
112. Robbins JD, Robbins JB. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 1984; 150:436-49; PMID:6207249; http://dx.doi.org/10.1093/infdis/150.3.436
113. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, Schulz D, Armand J, Bryla DA, Trollfors B, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 1987; 317:1101-4; PMID:3657877; http://dx.doi.org/10.1056/ NEJM198710293171801
114. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14:435-8; PMID:8735556; http://dx.doi.org/10.1016/0264-410X(95)00186-5
115. Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, Wang HF, Ding ZS, Yang Y, Tan WS, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001; 79:625-31; PMID:11477965
116. BioMed. Peda Typh. (cited 2014 Feb 11). Available from: http://biomed.co.in/typh-vaccine.html.
117. Biotech B. (cited 2014 Feb 11). Available from: http://www.bharatbiotech. com/.
118. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-9; PMID:11320385; http://dx.doi.org/10.1056/NEJM200104263441701
119. Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, Chu C, Schiloach J, Robbins JB, Schneerson R, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003; 349:1390-1; PMID:14523155; http://dx.doi.org/10.1056/NEJM200310023491423
120. van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, et al. Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One 2011; 6:e25398; PMID:21980445; http://dx.doi.org/10.1371/journal.pone.0025398
121. Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis 2014; 14:119-29; PMID:24290843; http://dx.doi.org/10.1016/S1473-3099(13)70241-X
122. Cui C, Carbis R, An SJ, Jang H, Czerkinsky C, Szu SC, Clemens JD. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010; 17:73-9; PMID:19889941; http://dx.doi.org/10.1128/ CVI.00266-09
123. An SJ, Yoon YK, Kothari S, Kothari N, Kim JA, Lee E, Kim DR, Park TH, Smith GW, Carbis R. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity. Vaccine 2011; 29:7618-23; PMID:21843575; http://dx.doi.org/10.1016/j.vaccine. 2011.08.019
124. An SJ, Yoon YK, Kothari S, Kim DR, Kim JA, Kothari N, Lee E, Park TH, Carbis R. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine. Vaccine 2012; 30:1023-8; PMID:22192846; http://dx.doi.org/10.1016/j.vaccine.2011.12.046
125. Lu YJ, Zhang F, Sayeed S, Thompson CM, Szu S, Anderson PW, Malley R. A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi. Vaccine 2012; 30:3405-12; PMID:22465750; http://dx.doi.org/10.1016/j. vaccine.2012.03.039
126. Ali A, An SJ, Cui C, Haque A, Carbis R. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid. Hum Vaccin Immunother 2012; 8:189-93; PMID:22426380; http://dx.doi.org/10.4161/hv.18350
127. Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 2005; 192:360-6; PMID:15995948; http://dx.doi.org/10.1086/431605
128. Kirkpatrick BD, Bentley MD, Thern AM, Larsson CJ, Ventrone C, Sreenivasan MV, Bourgeois L. Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cell assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09). Clin Diagn Lab Immunol 2005; 12:1127-9; PMID:16148184
129. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006; 24:116-23; PMID:16140433; http://dx.doi.org/10.1016/j. vaccine.2005.08.008
130. Jain SK. M-01ZH09, an oral live attenuated Salmonella enterica serovar Typhi vaccine for the prevention of typhoid fever. Curr Opin Mol Ther 2009; 11:565-71; PMID:19806505
131. Tran TH, Nguyen TD, Nguyen TT, Ninh TT, Tran NB, Nguyen VM, Tran TT, Cao TT, Pham VM, Nguyen TC, et al. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One 2010; 5:e11778; PMID:20668668; http://dx.doi.org/10.1371/journal.pone.0011778
132. Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, et al. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units. Vaccine 2010; 28:3602-8; PMID:20188175; http://dx.doi.org/10.1016/j.vaccine.2010.02.017
133. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect Immun 2000; 68:4647-52; PMID:10899868; http://dx.doi.org/10.1128/IAI.68.8.4647-4652.2000
134. Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM, Sztein MB. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 2007; 25:1416-25; PMID:17182155; http://dx.doi.org/10.1016/j.vaccine.2006.10.040
135. Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM, Sztein MB. Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol 2008; 1:389-98; PMID:19079203; http://dx.doi.org/10. 1038/mi.2008.30
136. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007; 45(Suppl 1):S20-3; PMID:17582563; http://dx.doi.org/10.1086/518135
137. Wahid R, Pasetti MF, Maciel M Jr., Simon JK, Tacket CO, Levine MM, Sztein MB. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin Immunol 2011; 138:187-200; PMID:21146460; http://dx.doi.org/10.1016/j.clim.2010.11.006
138. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173:1408-14; PMID:8648213; http://dx.doi.org/10.1093/infdis/173.6.1408
139. Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 1996; 14:19-24; PMID:8821644; http://dx.doi.org/10.1016/0264-410X(95) 00173-X
140. Secundino I, López-Macías C, Cervantes-Barragán L, Gil-Cruz C, Ríos-Sarabia N, Pastelin-Palacios R, Villasis-Keever MA, Becker I, Puente JL, Calva E, et al. Salmonella porins induce a sustained, lifelong specific bactericidal antibody memory response. Immunology 2006; 117:59-70; PMID:16423041; http://dx.doi.org/10.1111/j.1365-2567.2005.02263.x
141. Konadu E, Shiloach J, Bryla DA, Robbins JB, Szu SC. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect Immun 1996; 64:2709-15; PMID:8698499
142. Konadu EY, Lin FY, Hó VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas AB, Li J, et al. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 2000; 68:1529-34; PMID:10678970; http://dx.doi.org/10.1128/IAI.68.3.1529-1534. 2000
143. Sahastrabuddhe S, Carbis R, Wierzba TF, Ochiai RL. Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development. Expert Rev Vaccines 2013; 12:1021-31; PMID:24053396; http://dx.doi.org/10.1586/ 14760584.2013.825450
144. Micoli F, Rondini S, Gavini M, Lanzilao L, Medaglini D, Saul A, Martin LBO. O:2-CRM(197) conjugates against Salmonella Paratyphi A. PLoS One 2012; 7:e47039; PMID:23144798; http://dx.doi.org/10.1371/journal.pone.0047039
145. Micoli F, Rondini S, Gavini M, Pisoni I, Lanzilao L, Colucci AM, Giannelli C, Pippi F, Sollai L, Pinto V, et al. A scalable method for O-antigen purification applied to various Salmonella serovars. Anal Biochem 2013; 434:136-45; PMID:23142430; http://dx.doi.org/10.1016/j.ab.2012.10.038
146. Svenson SB, Nurminen M, Lindberg AA. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infect Immun 1979; 25:863-72; PMID:387597
147. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, Ghaem-Maghami M, Sexton A, Khan M, Brennan FR, et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 2002; 70:3457-67; PMID:12065485; http://dx.doi.org/10.1128/IAI.70.7.3457-3467.2002
148. Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, Gat O, Levine MM. Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun 2011; 79:4175-85; PMID:21807911; http://dx.doi.org/10.1128/IAI.05278-11
149. Choi J, Shin D, Ryu S. Salmonella enterica serovar Typhimurium ruvB mutant can confer protection against salmonellosis in mice. Vaccine 2010; 28:6436-44; PMID:20670908; http://dx.doi.org/10.1016/j.vaccine.2010.07.048
150. Allam US, Krishna MG, Lahiri A, Joy O, Chakravortty D. Salmonella enterica serovar Typhimurium lacking hfq gene confers protective immunity against murine typhoid. PLoS One 2011; 6:e16667; PMID:21347426; http://dx.doi.org/10.1371/journal.pone.0016667
151. Pesciaroli M, Aloisio F, Ammendola S, Pistoia C, Petrucci P, Tarantino M, Francia M, Battistoni A, Pasquali P. An attenuated Salmonella enterica serovar Typhimurium strain lacking the ZnuABC transporter induces protection in a mouse intestinal model of Salmonella infection. Vaccine 2011; 29:1783-90; PMID:21219981; http://dx.doi.org/10.1016/j.vaccine.2010.12.111
152. Vishwakarma V, Pati NB, Chandel HS, Sahoo SS, Saha B, Suar M. Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice. PLoS One 2012; 7:e52043; PMID:23284865; http://dx.doi.org/10.1371/journal.pone.0052043
153. Heithoff DM, Sinsheimer RL, Low DA, Mahan MJ. An essential role for DNA adenine methylation in bacterial virulence. Science 1999; 284:967-70; PMID:10320378; http://dx.doi.org/10.1126/science.284.5416.967
154. Heithoff DM, Enioutina EY, Daynes RA, Sinsheimer RL, Low DA, Mahan MJ. Salmonella DNA adenine methylase mutants confer cross-protective immunity. Infect Immun 2001; 69:6725-30; PMID:11598044; http://dx.doi.org/10.1128/IAI.69. 11.6725-6730.2001
155. Kong W, Wanda SY, Zhang X, Bollen W, Tinge SA, Roland KL, Curtiss R 3rd. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. Proc Natl Acad Sci U S A 2008; 105:9361-6; PMID:18607005; http://dx.doi.org/10.1073/pnas.0803801105
156. Li Y, Wang S, Scarpellini G, Gunn B, Xin W, Wanda SY, Roland KL, Curtiss R 3rd. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci U S A 2009; 106:593-8; PMID:19114649; http://dx.doi.org/10.1073/pnas.0811697106
157. Curtiss R 3rd, Wanda SY, Gunn BM, Zhang X, Tinge SA, Ananthnarayan V, Mo H, Wang S, Kong W. Salmonella enterica serovar typhimurium strains with regulated delayed attenuation in vivo. Infect Immun 2009; 77:1071-82; PMID:19103774; http://dx.doi.org/10.1128/IAI.00693-08
158. Berlanda Scorza F, Doro F, Rodríguez-Ortega MJ, Stella M, Liberatori S, Taddei AR, Serino L, Gomes Moriel D, Nesta B, Fontana MR, et al. Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant. Mol Cell Proteomics 2008; 7:473-85; PMID:17982123; http://dx.doi.org/10.1074/mcp.M700295-MCP200
159. Pagliusi S, Leite LC, Datla M, Makhoana M, Gao Y, Suhardono M, Jadhav S, Harshavardhan GV, Homma A. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all. Vaccine 2013; 31(Suppl 2):B176-83; PMID:23598479; http://dx.doi.org/10.1016/j.vaccine.2012.11. 060
160. International Vaccine Institute. (cited 2014 Feb 11). Available from: http://www.ivi.int.
161. Novartis Vaccines Institute for Global Health. (cited 2014 Feb 11). Available from: http://www.nibr.com/research/developing-world/NVGH/index.shtml.
162. University of Maryland School of Medicine. Center for Vaccine Development. (cited 2014 Feb 11). Available from: http://medschool.umaryland. edu/cvd/.
163. Podda A, Saul AJ, Arora R, Bhutta Z, Sinha A, Gaind R, Singhal T, Saha S, Brooks A, Martin LB, et al. Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009. J Infect Dev Ctries 2010; 4:404-11; PMID:20601795
164. Feasey NA, Archer BN, Heyderman RS, Sooka A, Dennis B, Gordon MA, Keddy KH. Typhoid fever and invasive nontyphoid salmonellosis, Malawi and South Africa. Emerg Infect Dis 2010; 16:1448-51; PMID:20735930; http://dx.doi.org/10. 3201/eid1609.100125
165. Micoli F, Rondini S, Pisoni I, Giannelli C, Di Cioccio V, Costantino P, Saul A, Martin LB. Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi. Vaccine 2012; 30:853-61; PMID:22172503; http://dx.doi.org/10.1016/j.vaccine.2011.11.108
166. Micoli F, Rondini S, Pisoni I, Proietti D, Berti F, Costantino P, Rappuoli R, Szu S, Saul A, Martin LB. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 2011; 29:712-20; PMID:21115057; http://dx.doi.org/10.1016/j.vaccine.2010.11.022
167. Rondini S, Micoli F, Lanzilao L, Hale C, Saul AJ, Martin LB. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi. Clin Vaccine Immunol 2011; 18:460-8; PMID:21248155; http://dx.doi.org/10.1128/CVI. 00387-10
168. Killeen KP, Griffin TJ, Cartee RT, Thanawastien A. Development of protein capsular matrix platform technology. BioProcess International 2013; 11:S26-32
169. Kothari S, Kim JA, Kothari N, Jones C, Choe WS, Carbis R. Purification of O-specific polysaccharide from lipopolysaccharide produced by Salmonella enterica serovar Paratyphi A. Vaccine 2014; 32:2457-62; PMID:24631090; http://dx.doi.org/10.1016/j.vaccine.2014.02.090
170. Galen JE, Simon R, Ernst RK. Salmonella expressing detoxified lipopolysaccharide is immunogenic and protective both as an attenuated vaccine and for delivery of foreign antigens. Expert Rev Vaccines 2011; 10:1679-82; PMID:22085171; http://dx.doi.org/10.1586/erv.11.155
171. Salazar-González RM, Maldonado-Bernal C, Ramírez-Cruz NE, Rios-Sarabia N, Beltrán-Nava J, Castañón-González J, Castillo-Torres N, Palma-Aguirre JA, Carrera-Camargo M, López- Macías C, et al. Induction of cellular immune response and anti-Salmonella enterica serovar typhi bactericidal antibodies in healthy volunteers by immunization with a vaccine candidate against typhoid fever. Immunol Lett 2004; 93:115-22; PMID:15158606; http://dx.doi.org/10.1016/j.imlet. 2004.01.010
172. Toobak H, Rasooli I, Talei D, Jahangiri A, Owlia P, Darvish Alipour Astaneh S. Immune response variations to Salmonella enterica serovar Typhi recombinant porin proteins in mice. Biologicals 2013; 41:224-30; PMID:23796754; http://dx.doi.org/10.1016/j.biologicals.2013.05.005
173. Berlanda Scorza F, Colucci AM, Maggiore L, Sanzone S, Rossi O, Ferlenghi I, Pesce I, Caboni M, Norais N, Di Cioccio V, et al. High yield production process for Shigella outer membrane particles. PLoS One 2012; 7:e35616; PMID:22701551; http://dx.doi.org/10.1371/journal.pone.0035616
174. Koeberling O, Ispasanie E, Hauser J, Rossi O, Pluschke G, Caugant DA, Saul A, Maclennan CA. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA). Vaccine 2014; 32:2688-95; PMID:24704334; http://dx.doi.org/10.1016/j. vaccine.2014.03.068
175. Clementz T, Bednarski JJ, Raetz CR. Function of the htrB high temperature requirement gene of Escherchia coli in the acylation of lipid A: HtrB catalyzed incorporation of laurate. J Biol Chem 1996; 271:12095-102; PMID:8662613; http://dx.doi.org/10.1074/jbc.271.20.12095
176. Clementz T, Zhou Z, Raetz CR. Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A. Acylation by MsbB follows laurate incorporation by HtrB. J Biol Chem 1997; 272:10353-60; PMID:9099672; http://dx.doi.org/10.1074/jbc.272.16.1035